An antiviral medicine targeting COVID-19 has progressed to Phase 3 clinical trials in China. Called JS016, the anti-COVID-19 candidate was developed by both the Institute of Microbiology, part of the Chinese Academy of Sciences, and Shanghai Junshi Biosciences, Ltd. Chinese press claims that JS016 is the first monoclonal antibody targeting COVID-19 administered to healthy people in clinical trials. This may be an exaggeration, as monoclonal antibodies from AstraZeneca have been tested for pre-exposure prophylaxis. But the investigational product developed by the two Chinese partners was licensed by Eli Lilly as part of its combination monoclonal antibody for COVID-19.
Recently the study teams completed a multi-site, multi-national Phase 2 clinical trial with positive results—indicating a safe and effective treatment. According to Yan Jinghua, a researcher with the Institute of Microbiology “The drug has been used for emergency treatment in 15 countries, and more than 500,000 doses have been sent overseas.”
The first patient to receive an infusion occurred at Shanghai-based Huashan Hospital of Fudan University. Prior to Phase 1, preclinical testing included primate subj...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).